MENU
+Compare
NPCE
Stock ticker: NASDAQ
AS OF
Jun 26, 04:59 PM (EDT)
Price
$10.93
Change
+$0.36 (+3.41%)
Capitalization
385.2M

NPCE Neuropace Forecast, Technical & Fundamental Analysis

NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures... Show more

NPCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for NPCE with price predictions
Jun 25, 2025

NPCE in upward trend: price expected to rise as it breaks its lower Bollinger Band on June 13, 2025

NPCE may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In of 31 cases where NPCE's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for NPCE's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NPCE advanced for three days, in of 227 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on June 11, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on NPCE as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for NPCE turned negative on May 28, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at .

NPCE moved below its 50-day moving average on June 11, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for NPCE crossed bearishly below the 50-day moving average on June 12, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where NPCE declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for NPCE entered a downward trend on June 25, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (18.657) is normal, around the industry mean (24.307). P/E Ratio (0.000) is within average values for comparable stocks, (77.706). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (5.667). Dividend Yield (0.000) settles around the average of (0.018) among similar stocks. P/S Ratio (5.371) is also within normal values, averaging (42.612).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. NPCE’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NPCE’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 90, placing this stock worse than average.

View a ticker or compare two or three
NPCE
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

NPCE is expected to report earnings to rise 6.76% to -22 cents per share on August 07

Neuropace NPCE Stock Earnings Reports
Q2'25
Est.
$-0.22
Q1'25
Beat
by $0.03
Q4'24
Beat
by $0.07
Q3'24
Beat
by $0.08
Q2'24
Beat
by $0.04
The last earnings report on May 13 showed earnings per share of -20 cents, beating the estimate of -23 cents. With 222.12K shares outstanding, the current market capitalization sits at 385.20M.
A.I. Advisor
published General Information

General Information

Industry MedicalSpecialties

Profile
Fundamentals
Details
Industry
N/A
Address
455 N. Bernardo Avenue
Phone
+1 650 237-2700
Employees
167
Web
https://www.neuropace.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
WASCX20.630.12
+0.59%
Macquarie Asset Strategy Fund Cl C
BAGAX14.18N/A
N/A
Brown Advisory Growth Equity Adv
LKBLX52.60N/A
N/A
LK Balanced Institutional
LGCVX18.57N/A
N/A
Lord Abbett Global Equity R5
UCNQX52.93N/A
N/A
Victory Nasdaq 100 Index C

NPCE and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, NPCE has been loosely correlated with STVN. These tickers have moved in lockstep 37% of the time. This A.I.-generated data suggests there is some statistical probability that if NPCE jumps, then STVN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NPCE
1D Price
Change %
NPCE100%
-1.77%
STVN - NPCE
37%
Loosely correlated
+2.68%
TMCI - NPCE
31%
Poorly correlated
+0.84%
ATRC - NPCE
30%
Poorly correlated
-1.44%
NTRA - NPCE
30%
Poorly correlated
-4.49%
SMTI - NPCE
29%
Poorly correlated
-1.40%
More